Wednesday, 26 August 2026European Markets

ORDINA Stock Impressive Rise On Tuesday, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with ORDINA (ORDI.AS) rising 23.22% to €5.89 on Tuesday while AEX-Index jumped 0.98% to €736.18.

About ORDINA

Ordina N.V. provides IT services in the Netherlands, Belgium, and Luxembourg. It engages in the development and implementation of software solutions, as well as designing and managing IT landscapes. The company also provides consulting, technology, and outsourcing services. It serves customers in public, financial services, and industry sectors. Ordina N.V. was incorporated in 1973 and is headquartered in Nieuwegein, the Netherlands.

Earnings Per Share

As for profitability, ORDINA has a trailing twelve months EPS of €0.24.

PE Ratio

ORDINA has a trailing twelve months price to earnings ratio of 24.64. Meaning, the purchaser of the share is investing €24.64 for every euro of annual earnings.

Volume

Today's last reported volume for ORDINA is 12215100 which is 2449.79% above its average volume of 479064.

Volatility

ORDINA's last week, last month's, and last quarter's current intraday variation average was 4.09%, 1.10%, and 1.22%.

ORDINA's highest amplitude of average volatility was 4.09% (last week), 1.69% (last month), and 1.22% (last quarter).

More news about ORDINA (ORDI.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com